Literature DB >> 10390545

Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.

M J McCluskie1, C L Brazolot Millan, R A Gramzinski, H L Robinson, J C Santoro, J T Fuller, G Widera, J R Haynes, R H Purcell, H L Davis.   

Abstract

BACKGROUND: In spite of the large number of studies that have evaluated DNA-based immunization, few have directly compared the immune responses generated by different routes of immunization, particularly in non-human primates. Here we examine the ability of a hepatitis B surface antigen (HBsAg)-encoding plasmid to induce immune responses in mice and non-human primates (rhesus monkeys: Macaca mulatta) after delivery by a number of routes.
MATERIALS AND METHODS: Eight different injected [intraperitoneal (IP), intradermal (ID), intravenous (IV), intramuscular (IM), intraperineal (IPER), subcutaneous (SC), sublingual (SL), vaginal wall (VW)] and six noninjected [intranasal inhalation (INH), intranasal instillation (INS), intrarectal (IR), intravaginal (IVAG), ocular (Oc), oral feeding (oral)] routes and the gene gun (GG) were used to deliver HBsAg-expressing plasmid DNA to BALB/c mice. Sera were assessed for HBsAg-specific antibodies (anti-HBs, IgG, IgG1, IgG2a) and cytotoxic T lymphocyte (CTL) activity measured. Three of the most commonly used routes (IM, ID, GG) were compared in rhesus monkeys, also using HBsAg-expressing vectors. Monkeys were immunized with short (0-, 4- and 8-week) or long (0-, 12- and 24-week) intervals between boosts, and in the case of GG, also with different doses, and their sera were assessed for anti-HBs.
RESULTS: In one study, anti-HBs were detected in plasma of mice treated by five of eight of the injected and none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although significant titers were also obtained with SL and ID. Each of these routes also induced CTL, as did IPER and VW and one noninjected route (INH) that failed to induce antibodies. In a second study, GG (1.6 microg) was compared to ID and IM (100 microg) delivery. Significant titers were obtained by all routes after only one boost, with the highest levels detected by IM. Delivery to the skin by GG induced exclusively IgG1 antibodies (Th2-like) at 4 weeks and only very low IgG2a levels at later times; ID-immunized mice had predominantly IgG1 at 4 weeks and this changed to mixed IgG1/IgG2a over time. Responses with IM injection (in the leg or tongue) were predominantly IgG2a (Th1-like) at all times. IV injection gave mixed IgG1/IgG2a responses. In monkeys, in the first experiment, 1 mg DNA IM or ID at 0, 4, and 8 weeks gave equivalent anti-HB titers and 0.4 microg at the same times by GG induced lower titers. In the second experiment, 1 mg DNA IM or ID, or 3.2 microg by GG, at 0, 12, and 24 weeks, gave anti-HB values in the hierarchy of GG > IM > ID. Furthermore, high titers were retained after a single immunization in mice but fell off over time in the monkeys, even after boost.
CONCLUSIONS: Route of administration of plasmid DNA vaccines influences the strength and nature of immune responses in mice and non-human primates. However, the results in mice were not always predictive of those in monkeys and this is likely true for humans as well. Optimal dose and immunization schedule will most likely vary between species. It is not clear whether results in non-human primates will be predictive of results in humans, thus additional studies are required. http://link.springer-ny.com/link/service/journals/00020/bibs /5n5p287. html

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390545      PMCID: PMC2230426     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  81 in total

1.  Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids.

Authors:  R Wang; D L Doolan; Y Charoenvit; R C Hedstrom; M J Gardner; P Hobart; J Tine; M Sedegah; V Fallarme; J B Sacci; M Kaur; D M Klinman; S L Hoffman; W R Weiss
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

2.  DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans.

Authors:  K E Ugen; S B Nyland; J D Boyer; C Vidal; L Lera; S Rasheid; M Chattergoon; M L Bagarazzi; R Ciccarelli; T Higgins; Y Baine; R Ginsberg; R R Macgregor; D B Weiner
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

3.  CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.

Authors:  M J McCluskie; H L Davis
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

4.  Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.

Authors:  A M Krieg; T Wu; R Weeratna; S M Efler; L Love-Homan; L Yang; A K Yi; D Short; H L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

5.  Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines.

Authors:  M Daheshia; N Kuklin; E Manickan; S Chun; B T Rouse
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

6.  Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells.

Authors:  M A Chattergoon; T M Robinson; J D Boyer; D B Weiner
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

7.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

8.  Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

Authors:  S Calarota; G Bratt; S Nordlund; J Hinkula; A C Leandersson; E Sandström; B Wahren
Journal:  Lancet       Date:  1998-05-02       Impact factor: 79.321

9.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response.

Authors:  R R MacGregor; J D Boyer; K E Ugen; K E Lacy; S J Gluckman; M L Bagarazzi; M A Chattergoon; Y Baine; T J Higgins; R B Ciccarelli; L R Coney; R S Ginsberg; D B Weiner
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Authors:  J F Richmond; S Lu; J C Santoro; J Weng; S L Hu; D C Montefiori; H L Robinson
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  43 in total

1.  Intralymphatic immunization enhances DNA vaccination.

Authors:  K J Maloy; I Erdmann; V Basch; S Sierro; T A Kramps; R M Zinkernagel; S Oehen; T M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 2.  Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization.

Authors:  R J Mumper; H C Ledebur
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

3.  Expression of domain III of the envelope protein from GP-78: a Japanese encephalitis virus.

Authors:  Sahil Kulkarni; Sandeepan Mukherjee; Krishna Mohan Padmanabha Das; Kaushiki Prabhudesai; Nupur Deshpande; Sushant Karnik; Abhay S Chowdhary; Usha Padmanabhan
Journal:  Virusdisease       Date:  2017-05-25

4.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 5.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 6.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

7.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation.

Authors:  David Hallengärd; B Kristian Haller; Anna-Karin Maltais; Eva Gelius; Kopek Nihlmark; Britta Wahren; Andreas Bråve
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease.

Authors:  Jan G Schiltz; Ulrich Salzer; M Hasan Mohajeri; Daniel Franke; Jochen Heinrich; Jovan Pavlovic; M Axel Wollmer; Roger M Nitsch; Karin Moelling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.